Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Rises By 122.3%

Key Points

• Short interest in SOPHiA GENETICS increased by 122.3% in August, with a total of 40,900 shares sold short.
• Several institutional investors have increased their positions in the company, including Federated Hermes Inc. with a 89.0% increase in shares.
• The company reported an earnings per share (EPS) of $0.33 for the last quarter, exceeding analyst expectations of ($0.25).

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totaling 40,900 shares, agrowthof122.3% from the July 31st total of 18,400 shares. Currently,0.1% of the shares of the company are sold short. Based on an average daily volume of 96,700 shares, the short-interest ratio is currently 0.4 days. Based on an average daily volume of 96,700 shares, the short-interest ratio is currently 0.4 days. Currently,0.1% of the shares of the company are sold short.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its holdings in SOPHiA GENETICS by 23.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company's stock valued at $68,000 after buying an additional 4,115 shares during the last quarter. Millennium Management LLC grew its holdings in SOPHiA GENETICS by 6.5% during the 4th quarter. Millennium Management LLC now owns 698,634 shares of the company's stock valued at $2,180,000 after buying an additional 42,689 shares during the last quarter. Silverberg Bernstein Capital Management LLC grew its holdings in SOPHiA GENETICS by 54.4% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 34,675 shares of the company's stock valued at $115,000 after buying an additional 12,211 shares during the last quarter. Bank Pictet & Cie Europe AG grew its holdings in SOPHiA GENETICS by 14.4% during the 1st quarter. Bank Pictet & Cie Europe AG now owns 255,200 shares of the company's stock valued at $847,000 after buying an additional 32,200 shares during the last quarter. Finally, Ridgewood Investments LLC grew its holdings in SOPHiA GENETICS by 1,930.5% during the 1st quarter. Ridgewood Investments LLC now owns 40,610 shares of the company's stock valued at $135,000 after buying an additional 38,610 shares during the last quarter. Institutional investors and hedge funds own 31.59% of the company's stock.

SOPHiA GENETICS Price Performance

SOPH stock traded up $0.08 during mid-day trading on Monday, reaching $3.32. 34,620 shares of the company's stock were exchanged, compared to its average volume of 73,321. The company has a market cap of $224.37 million, a price-to-earnings ratio of -7.55 and a beta of 1.01. The stock's 50 day moving average is $3.37 and its 200 day moving average is $3.18. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.39 and a quick ratio of 3.21. SOPHiA GENETICS has a 12-month low of $2.58 and a 12-month high of $4.92.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.33 EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.58. SOPHiA GENETICS had a negative return on equity of 30.69% and a negative net margin of 40.99%.The firm had revenue of $18.32 million for the quarter, compared to the consensus estimate of $17.49 million. SOPHiA GENETICS has set its FY 2025 guidance at EPS. On average, research analysts expect that SOPHiA GENETICS will post -0.96 EPS for the current year.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.